Allogeneic Hematopoietic Stem Cell Transplantation in the Treatment of Human C1q Deficiency: The Karolinska Experience

Transplantation

Volumn 100, Issue 6, 2016, Pages 1356-1362

  Olsson, Richard F ^a,b,c   Hagelberg, Stefan ^a   Schiller, Bodil ^b   Ringdén, Olle ^a,b   Truedsson, Lennart ^d   Åhlin, Anders ^b  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b KAROLINSKA INSTITUTE   (Sweden)

^c UPPSALA UNIVERSITY   (Sweden)

^d LUND UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINUCLEAR ANTIBODY; AZATHIOPRINE; COMPLEMENT COMPONENT C1Q; CYCLOSPORIN A; FLUDARABINE; GRANULOCYTE COLONY STIMULATING FACTOR; HYDROXYCHLOROQUINE; MENINGOCOCCUS VACCINE; METHOTREXATE; OCTAPLAS; PENICILLIN V; PREDNISOLONE; RIBONUCLEOPROTEIN ANTIBODY; RITUXIMAB; RO ANTIBODY; THYMOCYTE ANTIBODY; TREOSULFAN; VALACICLOVIR; CORTISONE; CYCLOSPORIN;

ABDOMINAL PAIN; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; BRAIN HEMORRHAGE; CHILD; CHIMERA; CLINICAL ARTICLE; COLONOSCOPY; COMPLEMENT C1Q DEFICIENCY; COMPLEMENT CLASSICAL PATHWAY; COMPLEMENT DEFICIENCY; DEATH; DIARRHEA; DISCOID LUPUS ERYTHEMATOSUS; DISEASE SEVERITY; DONOR LYMPHOCYTE INFUSION; ENGRAFTMENT; EPIDEMIC MENINGITIS; EPSTEIN BARR VIRUS INFECTION; FEMALE; FEVER; GENE MUTATION; GENERAL CONDITION DETERIORATION; GLOMERULONEPHRITIS; GRAFT VERSUS HOST REACTION; HERPES ZOSTER; HOMOZYGOSITY; HUMAN; LYMPHADENOPATHY; LYMPHOCYTOPENIA; MALE; MESENCHYMAL STEM CELL TRANSPLANTATION; MINIMUM PLASMA CONCENTRATION; MULTIPLE ORGAN FAILURE; PLASMAPHERESIS; POSTTRANSPLANT LYMPHOPROLIFERATIVE DISEASE; PRIORITY JOURNAL; SCHOOL CHILD; SEPTIC SHOCK; SYSTEMIC LUPUS ERYTHEMATOSUS; VIRUS REACTIVATION; ADOLESCENT; ADULT; ADVERSE EFFECTS; ALLOTRANSPLANTATION; CASE REPORT; DEFICIENCY; FATALITY; GASTROINTESTINAL DISEASES; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HETEROZYGOTE; INFANT; IRAQ; LUPUS ERYTHEMATOSUS, SYSTEMIC; LYMPHOPROLIFERATIVE DISORDERS; MORTALITY; POSTOPERATIVE COMPLICATION; PRESCHOOL CHILD; PROCEDURES; SWEDEN; TIME FACTOR; TRANSPLANTATION CONDITIONING; TREATMENT OUTCOME;

ADOLESCENT; ADULT; CHILD; CHILD, PRESCHOOL; COMPLEMENT C1Q; CORTISONE; CYCLOSPORINE; FATAL OUTCOME; FEMALE; GASTROINTESTINAL DISEASES; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HETEROZYGOTE; HUMANS; INFANT; IRAQ; LUPUS ERYTHEMATOSUS, SYSTEMIC; LYMPHOPROLIFERATIVE DISORDERS; MALE; METHOTREXATE; POSTOPERATIVE COMPLICATIONS; RITUXIMAB; SWEDEN; TIME FACTORS; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME;

EID: 84939563568     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0000000000000975     Document Type: Article

References (37)

1. Schejbel L, Skattum L, Hagelberg S, Molecular basis of hereditary C1q deficiency-revisited: identification of several novel disease-causing mutations. Genes Immun. 2011; 12: 626-634.
2. Skattum L, van Deuren M, van der Poll T, Complement deficiency states and associated infections. Mol Immunol. 2011; 48: 1643-1655.
3. Sturfelt G, Truedsson L,. Complement in the immunopathogenesis of rheumatic disease. Nat Rev Rheumatol. 2012; 8: 458-468.
4. Bowness P, Davies KA, Norsworthy PJ, Hereditary C1q deficiency and systemic lupus erythematosus. QJM. 1994; 87: 455-464.
5. Walport MJ, Davies KA, Botto M,. C1q and systemic lupus erythematosus. Immunobiology. 1998; 199: 265-285.
6. Pickering MC, Botto M, Taylor PR, Systemic lupus erythematosus, complement deficiency, and apoptosis. Adv Immunol. 2000; 76: 227-324.
7. Al-Mayouf SM, Abanomi H, Eldali A,. Impact of C1q deficiency on the severity and outcome of childhood systemic lupus erythematosus. Int J Rheum Dis. 2011; 14: 81-85.
8. Rabs U, Martin H, Hitschold T, Isolation and characterization of macrophage-derived C1q and its similarities to serum C1q. Eur J Immunol. 1986; 16: 1183-1186.
9. Zhou AQ, Herriott MJ, Leu RW,. Kinetics of the biosynthesis of complement subcomponent C1q by murine macrophages: LPS, immune complexes, and zymosan alone and in combination with interferon-gamma. J Leukoc Biol. 1991; 50: 453-463.
10. Cortes-Hernandez J, Fossati-Jimack L, Petry F, Restoration of C1q levels by bone marrow transplantation attenuates autoimmune disease associated with C1q deficiency in mice. Eur J Immunol. 2004; 34: 3713-3722.
11. Izzet Berkel A, Sanal O, Thesen R, A case of selective Clq deficiency. Turk J Pediatr. 1977; 19: 101-108.
12. Mehta P, Norsworthy PJ, Hall AE, SLE with C1q deficiency treated with fresh frozen plasma: A 10-year experience. Rheumatology (Oxford). 2010; 49: 823-824.
13. Olsson R, Hagelberg S, Ringden O, Allogeneic haematopoietic stem cell transplantation restores complement function in human hereditary C1q deficiency. Bone Marrow Transplant. 2013; 48: 338.
14. Arkwright PD, Riley P, Hughes SM, Successful cure of C1q deficiency in human subjects treated with hematopoietic stem cell transplantation. J Allergy Clin Immunol. 2014; 133: 265-267.
15. Olsson R, Hagelberg S, Schiller B, Allogeneic haematopoietic stem cell transplantation in the treatment for human C1q deficiency-The Karolinska experience. Bone Marrow Transplant. 2015; 50: 489.
16. Johnson U, Truedsson L, Gustavii B,. Complement components in 100 newborns and their mothers determined by electroimmunoassay. Acta Pathol Microbiol Immunol Scand C. 1983; 91: 147-150.
17. Seelen MA, Roos A, Wieslander J, Functional analysis of the classical, alternative, and MBL pathways of the complement system: standardization and validation of a simple ELISA. J Immunol Methods. 2005; 296: 187-198.
18. Lood C, Gullstrand B, Truedsson L, C1q inhibits immune complex-induced interferon-Alpha production in plasmacytoid dendritic cells: A novel link between C1q deficiency and systemic lupus erythematosus pathogenesis. Arthritis Rheum. 2009; 60: 3081-3090.
19. Svahn BM, Remberger M, Myrbäck KE, Home care during the pancytopenic phase after allogeneic hematopoietic stem cell transplantation is advantageous compared with hospital care. Blood. 2002; 100: 4317-4324.
20. Ringdén O, Remberger M, Svenberg P, Fludarabine-based disease-specific conditioning or conventional myeloablative conditioning in hematopoietic stem cell transplantation for treatment of non-malignant diseases. Bone Marrow Transplant. 2007; 39: 383-388.
21. Storb R, Deeg HJ, Pepe M, Methotrexate and cyclosporine versus cyclosporine alone for prophylaxis of graft-versus-host disease in patients given HLA-identical marrow grafts for leukemia: long-Term follow-up of a controlled trial. Blood. 1989; 73: 1729-1734.
22. Karapirli M, Kizilgun M, Yesilyurt O, Simultaneous determination of cyclosporine A, tacrolimus, sirolimus, and everolimus in whole-blood samples by LC-MS/MS. ScientificWorldJournal. 2012; 2012: 571201.
23. Barrios M, Jiménez-Velasco A, Román-Gómez J, Chimerism status is a useful predictor of relapse after allogeneic stem cell transplantation for acute leukemia. Haematologica. 2003; 88: 801-810.
24. Svenberg P, Mattsson J, Ringdén O, Allogeneic hematopoietic SCT in patients with non-malignant diseases, and importance of chimerism. Bone Marrow Transplant. 2009; 44: 757-763.
25. Alizadeh M, Bernard M, Danic B, Quantitative assessment of hematopoietic chimerism after bone marrow transplantation by real-Time quantitative polymerase chain reaction. Blood. 2002; 99: 4618-4625.
26. Yago K, Itoh M, Shimada H,. Successful donor lymphocyte infusion for Epstein-Barr virus-Associated lymphoproliferative disorder after allogeneic bone marrow transplantation from an HLA 1-locus-mismatched sibling donor in a patient with acute lymphocytic leukemia. Rinsho Ketsueki. 2001; 42: 1105-1110.
27. Kanold J, Merlin E, Halle P, Photopheresis in pediatric graft-versus-host disease after allogeneic marrow transplantation: clinical practice guidelines based on field experience and review of the literature. Transfusion. 2007; 47: 2276-2289.
28. Ringdén O, Uzunel M, Rasmusson I, Mesenchymal stem cells for treatment of therapy-resistant graft-versus-host disease. Transplantation. 2006; 81: 1390-1397.
29. Tug S, Helmig S, Menke J, Correlation between cell free DNA levels and medical evaluation of disease progression in systemic lupus erythematosus patients. Cell Immunol. 2014; 292: 32-39.
30. Gooley TA, Chien JW, Pergam SA, Reduced mortality after allogeneic hematopoietic-cell transplantation. N Engl J Med. 2010; 363: 2091-2101.
31. Horan JT, Logan BR, Agovi-Johnson MA, Reducing the risk for transplantation-related mortality after allogeneic hematopoietic cell transplantation: how much progress has been made? J Clin Oncol. 2011; 29: 805-813.
32. Remberger M, Ackefors M, Berglund S, Improved survival after allogeneic hematopoietic stem cell transplantation in recent years. A single-center study. Biol Blood Marrow Transplant. 2011; 17: 1688-1697.
33. Willasch A, Hoelle W, Kreyenberg H, Outcome of allogeneic stem cell transplantation in children with non-malignant diseases. Haematologica. 2006; 91: 788-794.
34. Sundin M, Le Blanc K, Ringdén O, The role of HLA mismatch, splenectomy and recipient Epstein-Barr virus seronegativity as risk factors in post-Transplant lymphoproliferative disorder following allogeneic hematopoietic stem cell transplantation. Haematologica. 2006; 91: 1059-1067.
35. Landgren O, Gilbert ES, Rizzo JD, Risk factors for lymphoproliferative disorders after allogeneic hematopoietic cell transplantation. Blood. 2009; 113: 4992-5001.
36. Andreani M, Testi M, Lucarelli G,. Mixed chimerism in haemoglobinopathies: from risk of graft rejection to immune tolerance. Tissue Antigens. 2014; 83: 137-146.
37. Stikvoort A, Gertow J, Sundin M, Chimerism patterns of long-Term stable mixed chimeras posthematopoietic stem cell transplantation in patients with nonmalignant diseases: follow-up of long-Term stable mixed chimerism patients. Biol Blood Marrow Transplant. 2013; 19: 838-844.